Nikolaj Frost
YOU?
Author Swipe
View article: Independent Validation of a Machine Learning Classifier for Predicting Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer Using Routinely Obtainable [18F]FDG-PET/CT Parameters
Independent Validation of a Machine Learning Classifier for Predicting Mediastinal Lymph Node Metastases in Non-Small Cell Lung Cancer Using Routinely Obtainable [18F]FDG-PET/CT Parameters Open
In non-small cell lung cancer (NSCLC), [18F]FDG-PET/CT is limited in pretherapeutic lymph node (LN) staging by false-positives. We previously demonstrated that a machine learning (ML) classifier using routine [18F]FDG-PET/CT and clinical v…
View article: AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer
AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer Open
Risk stratification remains a critical challenge in non-small cell lung cancer patients for optimal therapy selection. In this study, we develop an artificial intelligence-powered spatial cellomics approach that combines histology, multipl…
View article: Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West
Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West Open
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of Alzheimer’s disease. Here, we report on the clinical history and outcomes of the first 70 patients at the University of U…
View article: First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study Open
Overall survival with first-line nivolumab/ipilimumab in the real-world setting is comparable to the CM-743 results among trial-eligible patients, especially with non-epithelioid tumors, but shorter for the unselected cohort. IrAEs, in par…
View article: RMTD-05 PERI-OPERATIVE DEXAMETHASONE USE IN BRAIN METASTASIS SURGERY: ANALYSIS OF PRACTICE VARIATION ACROSS EIGHT NEUROSURGICAL CENTERS
RMTD-05 PERI-OPERATIVE DEXAMETHASONE USE IN BRAIN METASTASIS SURGERY: ANALYSIS OF PRACTICE VARIATION ACROSS EIGHT NEUROSURGICAL CENTERS Open
BACKGROUND Peri-operative corticosteroids are routinely administered in brain metastasis surgery to manage edema, yet standardized dosing protocols are lacking. Practice variation between neurosurgical centers has not been systematically q…
View article: In vivo prime editing rescues alternating hemiplegia of childhood in mice
In vivo prime editing rescues alternating hemiplegia of childhood in mice Open
View article: Recruiting patients into a healthcare services trial: lessons learned from a feasibility study to investigate a patient-oriented navigation intervention for age-associated diseases
Recruiting patients into a healthcare services trial: lessons learned from a feasibility study to investigate a patient-oriented navigation intervention for age-associated diseases Open
Background Interventions to improve care coordination, like patient navigation programs, aim to dismantle barriers faced by patients in accessing optimal care. A variety of interventions are currently being evaluated in Germany and interna…
View article: Re-resection of brain metastases – outcomes of an institutional cohort study and literature review
Re-resection of brain metastases – outcomes of an institutional cohort study and literature review Open
View article: Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy Open
Targeted or IO-based first-line treatment of BRAF-V600-mutated NSCLC has similar survival outcomes. Sex and PD-L1 status may support decision-making at the individual patient level.
View article: Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection
Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection Open
Importance Variations in perioperative dexamethasone dosing are common in brain metastasis resection, but their impact on patient outcomes remains unclear. Objective To evaluate the association between perioperative dexamethasone dosing an…
View article: Non-Small Cell Lung Cancer Patients with Skip-N2 Metastases Have Similar Survival to N1 Patients—A Multicenter Analysis
Non-Small Cell Lung Cancer Patients with Skip-N2 Metastases Have Similar Survival to N1 Patients—A Multicenter Analysis Open
Introduction: Nodal involvement is one of the most important prognostic factors in NSCLC. Skip-N2 metastasis (N0N2), which is N2 metastasis in the absence of N1 metastasis, occurs in approximately 20–30% of patients. According to the Inter…
View article: Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry
Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry Open
Introduction and objectives Leptomeningeal disease (LMD) involves disseminating cancer cells to the leptomeninges and cerebrospinal fluid. The impact of intracranial parenchymal brain metastases and extracranial disease burden at LMD diagn…
View article: First-Line Nivolumab Plus Ipilimumab in Pleural Mesothelioma: Efficacy and Safety Data from the Real-World MesoNet Study
First-Line Nivolumab Plus Ipilimumab in Pleural Mesothelioma: Efficacy and Safety Data from the Real-World MesoNet Study Open
View article: TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression
TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression Open
View article: 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study
117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study Open
View article: TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities Open
Thyroid transcription factor 1 (TTF-1) immunohistochemistry (IHC) is routinely used for the distinction of primary pulmonary adenocarcinomas. However, TTF-1 can also occur in other malignancies. A tissue microarray containing 17,772 sample…
View article: RMTD-02 PRACTICE VARIATION AND IMPACT OF PRE-OPERATIVE AND POST-OPERATIVE DEXAMETHASONE ON PATIENT OUTCOME IN THE RESECTED BRAIN METASTASIS – INSIGHTS FROM THE CLINDEXMET MULTICENTER REGISTRY
RMTD-02 PRACTICE VARIATION AND IMPACT OF PRE-OPERATIVE AND POST-OPERATIVE DEXAMETHASONE ON PATIENT OUTCOME IN THE RESECTED BRAIN METASTASIS – INSIGHTS FROM THE CLINDEXMET MULTICENTER REGISTRY Open
BACKGROUND Patients with brain metastases that undergo brain metastasis resection regularly receive perioperative dexamethasone. We sought to evaluate variation in pre- and post-operative dexamethasone dosing and whether perioperative dexa…
View article: 54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression Open
Background METΔ14ex is the driver alteration for approximately 3% of non-small cell lung cancers (NSCLC) and associated with a higher PD-L1 expression, but unclear benefit from immunotherapy (IO). Methods Seventy-eight consecutive patients…
View article: 156P The impact of the COVID-19 pandemic on the treatment patterns of patients with stage III unresectable non-small cell lung cancer
156P The impact of the COVID-19 pandemic on the treatment patterns of patients with stage III unresectable non-small cell lung cancer Open
The aim of this study was to understand the impact of the COVID-19 pandemic on the treatment patterns for patients with stage III unresectable non-small cell lung cancer (uNSCLC). This was a retrospective chart review study of stage III uN…
View article: Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection
Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection Open
Background Emerging evidence suggests that treatment of NSCLC brain metastases with immune checkpoint inhibitors (ICIs) is associated with response rates similar to those of extracranial disease. Programmed death-ligand 1 (PD-L1) tumor pro…
View article: Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany Open
First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutations seem to derive less benefit.
View article: First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations Open
View article: Prognostic Value of Thyroid Transcription Factor 1 Expression in Newly Diagnosed, Treatment-Naïve Non-Small-Cell Lung Cancer Adenocarcinoma Brain Metastasis
Prognostic Value of Thyroid Transcription Factor 1 Expression in Newly Diagnosed, Treatment-Naïve Non-Small-Cell Lung Cancer Adenocarcinoma Brain Metastasis Open
View article: Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer Open
G12C/TP53 comutations identify a subset of patients with a very favorable long-term survival with immune checkpoint inhibitor monotherapy, mediated by highly active interferon gamma signaling in a proinflammatory TME.
View article: TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading Open
TTF-1 status predicts relapse and survival in LUAD independently of tumor grading. The prognostic power of tumor grading is limited to TTF-1-positive patients, and the effect size of TTF-1 surpasses that of tumor grading. We recommend incl…
View article: Re-resection of brain metastases – Outcomes of an institutional cohort study and literature review
Re-resection of brain metastases – Outcomes of an institutional cohort study and literature review Open
Background: Surgically accessible brain metastases are treated with microsurgical removal followed by radiation therapy, resulting in improved progression-free and overall survival. Some patients experience recurrence, prompting the need f…
View article: Cell‐free <scp>DNA</scp> extraction from urine of lung cancer patients and healthy individuals: Evaluation of a simple method using sample volume up‐scaling
Cell‐free <span>DNA</span> extraction from urine of lung cancer patients and healthy individuals: Evaluation of a simple method using sample volume up‐scaling Open
Background Urine holds promise as a source for cell‐free DNA (cfDNA) analysis of cancer genetics due to its nature as a self‐collectable biospecimen available in large quantities. However, pre‐analytical variables such as preservation of c…
View article: 970 Multiplex-immunofluorescence-based spatial characterization of the tumor-microenvironment of a large bicentric clinical non-small cell lung cancer cohort
970 Multiplex-immunofluorescence-based spatial characterization of the tumor-microenvironment of a large bicentric clinical non-small cell lung cancer cohort Open
Background Non-small-cell lung cancer (NSCLC) is the leading cause for cancer death. Current targeted- and immuno-therapies are effective in a patient subset, but causes for resistance and the complexity of the immune reaction are difficul…
View article: Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity
Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity Open
Background Neurologic immune-related adverse events (irAE-n) are rare but severe toxicities of immune checkpoint inhibitor (ICI) treatment. To overcome diagnostic and therapeutic challenges, a better mechanistic understanding of irAE-n is …
View article: 1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany Open